Gulf International Bank UK Ltd cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 32.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,350 shares of the company’s stock after selling 9,200 shares during the quarter. Gulf International Bank UK Ltd’s holdings in IDEXX Laboratories were worth $3,599,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc grew its holdings in shares of IDEXX Laboratories by 0.3% during the 3rd quarter. Vanguard Group Inc now owns 8,918,451 shares of the company’s stock valued at $2,226,581,000 after purchasing an additional 23,970 shares during the last quarter. LaFleur & Godfrey LLC bought a new stake in IDEXX Laboratories during the 3rd quarter worth approximately $341,000. Federated Investors Inc. PA grew its holdings in IDEXX Laboratories by 16.9% during the 3rd quarter. Federated Investors Inc. PA now owns 588,433 shares of the company’s stock worth $146,908,000 after acquiring an additional 85,257 shares during the last quarter. Marshall Wace North America L.P. grew its holdings in IDEXX Laboratories by 166.9% during the 3rd quarter. Marshall Wace North America L.P. now owns 55,012 shares of the company’s stock worth $13,734,000 after acquiring an additional 34,404 shares during the last quarter. Finally, Great Lakes Advisors LLC grew its holdings in IDEXX Laboratories by 1.0% during the 3rd quarter. Great Lakes Advisors LLC now owns 13,766 shares of the company’s stock worth $3,437,000 after acquiring an additional 142 shares during the last quarter. 85.59% of the stock is currently owned by institutional investors.
NASDAQ:IDXX opened at $192.91 on Friday. IDEXX Laboratories, Inc. has a 52 week low of $166.70 and a 52 week high of $256.22. The firm has a market capitalization of $16.58 billion, a PE ratio of 58.81, a PEG ratio of 2.18 and a beta of 0.89.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, November 1st. The company reported $1.05 EPS for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.08. IDEXX Laboratories had a net margin of 15.19% and a negative return on equity of 994.76%. The company had revenue of $545.00 million for the quarter, compared to analyst estimates of $545.66 million. During the same period in the prior year, the firm posted $0.76 EPS. The company’s quarterly revenue was up 10.8% on a year-over-year basis. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 4.19 earnings per share for the current year.
In other news, Director Rebecca M. Henderson sold 3,504 shares of the company’s stock in a transaction on Tuesday, November 27th. The shares were sold at an average price of $194.92, for a total value of $682,999.68. Following the sale, the director now directly owns 22,200 shares of the company’s stock, valued at approximately $4,327,224. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Jacqueline Studer sold 3,313 shares of the company’s stock in a transaction on Tuesday, November 6th. The shares were sold at an average price of $201.27, for a total transaction of $666,807.51. The disclosure for this sale can be found here. Corporate insiders own 2.56% of the company’s stock.
IDXX has been the topic of a number of research reports. BidaskClub raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Tuesday, October 2nd. Bank of America reduced their target price on shares of IDEXX Laboratories from $275.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, November 2nd. Finally, Canaccord Genuity reduced their target price on shares of IDEXX Laboratories from $270.00 to $250.00 and set a “buy” rating on the stock in a report on Monday, November 5th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $252.33.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Further Reading: What is Considered a Good Return on Equity (ROE)?
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.